Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue: +32.0%
EPS: −296.6%
Free cash flow: −52.3%
Total debt: +599.5%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

55.89 0.23 −0.41%

Follow BMRN

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: 32.7×
Dividend yield: —
F-score: 5/9
Altman Z: 5.67
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BioMarin Pharmaceutical Inc. 8-K filed Sep 14, 2026

Period ended Sep 10, 2026 · Filed Sep 14, 2026 · accepted 9:26 AM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Red flags

Officer departure Sep 14, 2026
BioMarin Pharmaceutical Inc. reported the departure of an officer or director

8-K filed Sep 14, 2026 · The filing · sec.gov